MovDisordV3, Main, Exploration, bibRecord, 003B08

The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP‐treated primates

Identifieur interne : 003B08 ( Main/Exploration ); précédent : 003B07; suivant : 003B09

The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP‐treated primates

Auteurs : Matthew J. Hansard [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Sharon C. Cheetham [Royaume-Uni] ; Peter Jenner [Royaume-Uni]

Source :

Movement Disorders [ 0885-3185 ] ; 2004-01.

RBID : ISTEX:9786D3DEE263A88180D758AEAD02B14FDD26BBBF

Descripteurs français

Pascal (Inist)
- Dyskinésie, Inhibiteur recapture, Lévodopa, Primates, Système nerveux pathologie.

English descriptors

KwdEn :
- Animals, Antiparkinson Agents (pharmacology), BTS 74 398, Callithrix, Carbidopa (pharmacology), Chlorobenzenes (pharmacology), Cyclobutanes (pharmacology), Dopamine (physiology), Dopamine Uptake Inhibitors (pharmacology), Dose-Response Relationship, Drug, Drug Synergism, Dyskinesia, Dyskinesia, Drug-Induced (physiopathology), Levodopa, Levodopa (pharmacology), Locomotion (drug effects), Locomotion (physiology), MPTP, Male, Motor Activity (drug effects), Motor Activity (physiology), Motor Skills (drug effects), Motor Skills (physiology), Nervous system diseases, Neurologic Examination (drug effects), Parkinson's disease, Parkinsonian Disorders (physiopathology), Postural Balance (drug effects), Postural Balance (physiology), Primates, Reuptake inhibitor, Stereotyped Behavior (drug effects), Stereotyped Behavior (physiology), dyskinesia, marmosets.
MESH :
- chemical , pharmacology : Antiparkinson Agents, Carbidopa, Chlorobenzenes, Cyclobutanes, Dopamine Uptake Inhibitors, Levodopa.
- chemical , physiology : Dopamine.
- drug effects : Locomotion, Motor Activity, Motor Skills, Neurologic Examination, Postural Balance, Stereotyped Behavior.
- physiology : Locomotion, Motor Activity, Motor Skills, Postural Balance, Stereotyped Behavior.
- physiopathology : Dyskinesia, Drug-Induced, Parkinsonian Disorders.
- Animals, Callithrix, Dose-Response Relationship, Drug, Drug Synergism, Male.

Abstract

Long‐term treatment of Parkinson's disease (PD) with levodopa (L‐dopa) induces dyskinesia that, once established, is provoked by each dose of L‐dopa or a dopamine (DA) agonist. In contrast, monoamine reuptake inhibitors may reverse motor deficits in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐treated primates without provoking established involuntary movements. We now examine whether the potent monoamine reuptake blocker BTS 74 398 induces established dyskinesia in MPTP‐treated common marmosets primed previously with L‐dopa and whether co‐administration of BTS 74 398 with L‐dopa potentiates motor behaviour and dyskinesia induced by acute L‐dopa treatment. Administration of BTS 74 398 (2.5, 5.0, or 10.0 mg/kg, p.o.) in MPTP‐treated common marmosets increased locomotor activity and reduced motor disability in a dose‐related manner but did not provoke involuntary movements. BTS 74 398 (2.5, 5.0, or 10.0 mg/kg p.o.) co‐administered with a threshold dose of L‐dopa (2.5 mg/kg p.o.) did not evoke a motor response or induce dyskinesia. Similarly, concomitant administration of BTS 74 398 (5.0 mg/kg p.o.) with a submaximal L‐dopa dose (12.5 mg/kg p.o.) did not potentiate the motor response produced by L‐dopa alone and there was no alteration in the dyskinesia provoked by L‐dopa challenge. BTS 74 398 reverses motor abnormalities in MPTP‐treated marmosets without evoking established dyskinesia but no additive improvement occurs when administered in combination with L‐dopa. The lack of synergy with L‐dopa may suggest different sites of drug action. © 2003 Movement Disorder Society

Url:

https://api.istex.fr/document/9786D3DEE263A88180D758AEAD02B14FDD26BBBF/fulltext/pdf

DOI: 10.1002/mds.10596

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP‐treated primates</title>
<author><name sortKey="Hansard, Matthew J" sort="Hansard, Matthew J" uniqKey="Hansard M" first="Matthew J." last="Hansard">Matthew J. Hansard</name>
</author>
<author><name sortKey="Smith, Lance A" sort="Smith, Lance A" uniqKey="Smith L" first="Lance A." last="Smith">Lance A. Smith</name>
</author>
<author><name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J." last="Jackson">Michael J. Jackson</name>
</author>
<author><name sortKey="Cheetham, Sharon C" sort="Cheetham, Sharon C" uniqKey="Cheetham S" first="Sharon C." last="Cheetham">Sharon C. Cheetham</name>
</author>
<author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:9786D3DEE263A88180D758AEAD02B14FDD26BBBF</idno>
<date when="2004" year="2004">2004</date>
<idno type="doi">10.1002/mds.10596</idno>
<idno type="url">https://api.istex.fr/document/9786D3DEE263A88180D758AEAD02B14FDD26BBBF/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000F44</idno>
<idno type="wicri:Area/Istex/Curation">000F44</idno>
<idno type="wicri:Area/Istex/Checkpoint">002489</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Hansard M:the:monoamine:reuptake</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:14743355</idno>
<idno type="wicri:Area/PubMed/Corpus">003582</idno>
<idno type="wicri:Area/PubMed/Curation">003582</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003284</idno>
<idno type="wicri:Area/Ncbi/Merge">000C82</idno>
<idno type="wicri:Area/Ncbi/Curation">000C82</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000C82</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Hansard M:the:monoamine:reuptake</idno>
<idno type="wicri:Area/Main/Merge">005466</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:04-0234240</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002220</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000B01</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001F79</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Hansard M:the:monoamine:reuptake</idno>
<idno type="wicri:Area/Main/Merge">005817</idno>
<idno type="wicri:Area/Main/Curation">003B08</idno>
<idno type="wicri:Area/Main/Exploration">003B08</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP‐treated primates</title>
<author><name sortKey="Hansard, Matthew J" sort="Hansard, Matthew J" uniqKey="Hansard M" first="Matthew J." last="Hansard">Matthew J. Hansard</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurodegenerative Disease Research Centre, Guy's, King's and St. Thomas' School of Biomedical Sciences, King's College, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smith, Lance A" sort="Smith, Lance A" uniqKey="Smith L" first="Lance A." last="Smith">Lance A. Smith</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurodegenerative Disease Research Centre, Guy's, King's and St. Thomas' School of Biomedical Sciences, King's College, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J." last="Jackson">Michael J. Jackson</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurodegenerative Disease Research Centre, Guy's, King's and St. Thomas' School of Biomedical Sciences, King's College, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cheetham, Sharon C" sort="Cheetham, Sharon C" uniqKey="Cheetham S" first="Sharon C." last="Cheetham">Sharon C. Cheetham</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>RenaSci Consultancy Ltd., Nottingham</wicri:regionArea>
<wicri:noRegion>Nottingham</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurodegenerative Disease Research Centre, Guy's, King's and St. Thomas' School of Biomedical Sciences, King's College, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2004-01">2004-01</date>
<biblScope unit="vol">19</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="15">15</biblScope>
<biblScope unit="page" to="21">21</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">9786D3DEE263A88180D758AEAD02B14FDD26BBBF</idno>
<idno type="DOI">10.1002/mds.10596</idno>
<idno type="ArticleID">MDS10596</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiparkinson Agents (pharmacology)</term>
<term>BTS 74 398</term>
<term>Callithrix</term>
<term>Carbidopa (pharmacology)</term>
<term>Chlorobenzenes (pharmacology)</term>
<term>Cyclobutanes (pharmacology)</term>
<term>Dopamine (physiology)</term>
<term>Dopamine Uptake Inhibitors (pharmacology)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Synergism</term>
<term>Dyskinesia</term>
<term>Dyskinesia, Drug-Induced (physiopathology)</term>
<term>Levodopa</term>
<term>Levodopa (pharmacology)</term>
<term>Locomotion (drug effects)</term>
<term>Locomotion (physiology)</term>
<term>MPTP</term>
<term>Male</term>
<term>Motor Activity (drug effects)</term>
<term>Motor Activity (physiology)</term>
<term>Motor Skills (drug effects)</term>
<term>Motor Skills (physiology)</term>
<term>Nervous system diseases</term>
<term>Neurologic Examination (drug effects)</term>
<term>Parkinson's disease</term>
<term>Parkinsonian Disorders (physiopathology)</term>
<term>Postural Balance (drug effects)</term>
<term>Postural Balance (physiology)</term>
<term>Primates</term>
<term>Reuptake inhibitor</term>
<term>Stereotyped Behavior (drug effects)</term>
<term>Stereotyped Behavior (physiology)</term>
<term>dyskinesia</term>
<term>marmosets</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Carbidopa</term>
<term>Chlorobenzenes</term>
<term>Cyclobutanes</term>
<term>Dopamine Uptake Inhibitors</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Dopamine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Locomotion</term>
<term>Motor Activity</term>
<term>Motor Skills</term>
<term>Neurologic Examination</term>
<term>Postural Balance</term>
<term>Stereotyped Behavior</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Locomotion</term>
<term>Motor Activity</term>
<term>Motor Skills</term>
<term>Postural Balance</term>
<term>Stereotyped Behavior</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Callithrix</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Synergism</term>
<term>Male</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dyskinésie</term>
<term>Inhibiteur recapture</term>
<term>Lévodopa</term>
<term>Primates</term>
<term>Système nerveux pathologie</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Long‐term treatment of Parkinson's disease (PD) with levodopa (L‐dopa) induces dyskinesia that, once established, is provoked by each dose of L‐dopa or a dopamine (DA) agonist. In contrast, monoamine reuptake inhibitors may reverse motor deficits in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐treated primates without provoking established involuntary movements. We now examine whether the potent monoamine reuptake blocker BTS 74 398 induces established dyskinesia in MPTP‐treated common marmosets primed previously with L‐dopa and whether co‐administration of BTS 74 398 with L‐dopa potentiates motor behaviour and dyskinesia induced by acute L‐dopa treatment. Administration of BTS 74 398 (2.5, 5.0, or 10.0 mg/kg, p.o.) in MPTP‐treated common marmosets increased locomotor activity and reduced motor disability in a dose‐related manner but did not provoke involuntary movements. BTS 74 398 (2.5, 5.0, or 10.0 mg/kg p.o.) co‐administered with a threshold dose of L‐dopa (2.5 mg/kg p.o.) did not evoke a motor response or induce dyskinesia. Similarly, concomitant administration of BTS 74 398 (5.0 mg/kg p.o.) with a submaximal L‐dopa dose (12.5 mg/kg p.o.) did not potentiate the motor response produced by L‐dopa alone and there was no alteration in the dyskinesia provoked by L‐dopa challenge. BTS 74 398 reverses motor abnormalities in MPTP‐treated marmosets without evoking established dyskinesia but no additive improvement occurs when administered in combination with L‐dopa. The lack of synergy with L‐dopa may suggest different sites of drug action. © 2003 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Grand Londres</li>
</region>
<settlement><li>Londres</li>
</settlement>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Hansard, Matthew J" sort="Hansard, Matthew J" uniqKey="Hansard M" first="Matthew J." last="Hansard">Matthew J. Hansard</name>
</region>
<name sortKey="Cheetham, Sharon C" sort="Cheetham, Sharon C" uniqKey="Cheetham S" first="Sharon C." last="Cheetham">Sharon C. Cheetham</name>
<name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J." last="Jackson">Michael J. Jackson</name>
<name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name>
<name sortKey="Smith, Lance A" sort="Smith, Lance A" uniqKey="Smith L" first="Lance A." last="Smith">Lance A. Smith</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B08 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003B08 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:9786D3DEE263A88180D758AEAD02B14FDD26BBBF
   |texte=   The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP‐treated primates
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP‐treated primates

The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP‐treated primates

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.